Anheart, Foundation Medicine to develop CDx for ROS1 inhibitor taletrectinib
FoundationOne CDx and FoundationOne Liquid CDx are the company’s tissue-based and liquid-based comprehensive genomic profiling tests
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Dec 23
FoundationOne CDx and FoundationOne Liquid CDx are the company’s tissue-based and liquid-based comprehensive genomic profiling tests
15 Dec 23
The approval is based on the results of a multi-site, single-arm, externally controlled trial in which the addition…
15 Dec 23
This Sciex quadrupole time-of-flight high-resolution mass spectrometer is dedicated to GLP/GCP quantitation of oligonucleotide therapeutics and the planned…
14 Dec 23
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
14 Dec 23
The system includes a hollow-fibre module and draw solution for organic solvents to optimise the manufacturing processes in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 23
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
14 Dec 23
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
13 Dec 23
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…
13 Dec 23
The trial assessed Darzalex SC formulation-based quadruplet induction, consolidation regimen and doublet maintenance regimen in patients with transplant-eligible…